Targeted Intracellular Delivery of Antituberculosis Drugs to Mycobacterium tuberculosis-Infected Macrophages via Functionalized Mesoporous Silica Nanoparticles

ABSTRACT Delivery of antituberculosis drugs by nanoparticles offers potential advantages over free drug, including the potential to target specifically the tissues and cells that are infected by Mycobacterium tuberculosis, thereby simultaneously increasing therapeutic efficacy and decreasing systemic toxicity, and the capacity for prolonged release of drug, thereby allowing less-frequent dosing. We have employed mesoporous silica nanoparticle (MSNP) drug delivery systems either equipped with a polyethyleneimine (PEI) coating to release rifampin or equipped with cyclodextrin-based pH-operated valves that open only at acidic pH to release isoniazid (INH) into M. tuberculosis-infected macrophages. The MSNP are internalized efficiently by human macrophages, traffic to acidified endosomes, and release high concentrations of antituberculosis drugs intracellularly. PEI-coated MSNP show much greater loading of rifampin than uncoated MSNP and much greater efficacy against M. tuberculosis-infected macrophages. MSNP were devoid of cytotoxicity at the particle doses employed for drug delivery. Similarly, we have demonstrated that the isoniazid delivered by MSNP equipped with pH-operated nanovalves kill M. tuberculosis within macrophages significantly more effectively than an equivalent amount of free drug. These data demonstrate that MSNP provide a versatile platform that can be functionalized to optimize the loading and intracellular release of specific drugs for the treatment of tuberculosis.

[1]  G. P. Agrawal,et al.  Gelatin nanocarriers as potential vectors for effective management of tuberculosis. , 2010, International journal of pharmaceutics.

[2]  M. Thakur,et al.  Global tuberculosis control report. , 2001, The National medical journal of India.

[3]  Chin-Tu Chen,et al.  Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. , 2010, Biomaterials.

[4]  Niveen M. Khashab,et al.  Light-operated mechanized nanoparticles. , 2009, Journal of the American Chemical Society.

[5]  V. S. Lin.  Nanomedicine: Veni, vidi, vici and then... vanished. , 2009, Nature materials.

[6]  D. Scherman,et al.  A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Seeger,et al.  Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. , 2006, Toxicology and applied pharmacology.

[8]  Taeghwan Hyeon,et al.  Uniform mesoporous dye-doped silica nanoparticles decorated with multiple magnetite nanocrystals for simultaneous enhanced magnetic resonance imaging, fluorescence imaging, and drug delivery. , 2010, Journal of the American Chemical Society.

[9]  R. Pandey,et al.  Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. , 2005, Tuberculosis.

[10]  Yuyu Sun,et al.  Chitosan-based rechargeable long-term antimicrobial and biofilm-controlling systems. , 2009, Journal of biomedical materials research. Part A.

[11]  R. Reis,et al.  Cytokine secretion from mononuclear cells cultured in vitro with starch-based polymers and poly-L-lactide. , 2004, Journal of biomedical materials research. Part A.

[12]  J. F. Stoddart,et al.  Controlled-access hollow mechanized silica nanocontainers. , 2009, Journal of the American Chemical Society.

[13]  Xinying Wu,et al.  Reducing non-specific binding and uptake of nanoparticles and improving cell targeting with an antifouling PEO-b-PgammaMPS copolymer coating. , 2010, Biomaterials.

[14]  Monty Liong,et al.  Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. , 2007, Small.

[15]  Yuen A. Lau,et al.  Mechanised nanoparticles for drug delivery. , 2009, Nanoscale.

[16]  B. Nyström,et al.  Nanobead-based interventions for the treatment and prevention of tuberculosis , 2010, Nature Reviews Microbiology.

[17]  M. Horwitz,et al.  Virulent and Avirulent Strains of Francisella tularensis Prevent Acidification and Maturation of Their Phagosomes and Escape into the Cytoplasm in Human Macrophages , 2004, Infection and Immunity.

[18]  F. Cobelens,et al.  Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  S. Garg,et al.  Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. , 2003, The Journal of antimicrobial chemotherapy.

[20]  J. F. Stoddart,et al.  Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. , 2010, Journal of the American Chemical Society.

[21]  J. Estelrich,et al.  Chemical degradation of liposomes by serum components detected by NMR. , 2000, Chemistry and physics of lipids.

[22]  J. Zink,et al.  pH-Operated mechanized porous silicon nanoparticles. , 2011, Journal of the American Chemical Society.

[23]  Juan L. Vivero-Escoto,et al.  Capped mesoporous silica nanoparticles as stimuli-responsive controlled release systems for intracellular drug/gene delivery , 2010, Expert opinion on drug delivery.

[24]  N. Miceli,et al.  An improved micro spectrofluorometric assay for determining isoniazid in serum. , 1975, Biochemical medicine.

[25]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[26]  C. Barbé,et al.  Silica Particles: A Novel Drug‐Delivery System , 2004 .

[27]  Shuming Nie,et al.  Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. , 2007, Journal of the American Chemical Society.

[28]  Tian Xia,et al.  Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. , 2011, ACS nano.

[29]  Brian G Trewyn,et al.  Mesoporous silica nanomaterial-based biotechnological and biomedical delivery systems. , 2007, Nanomedicine.

[30]  J. Fraser Stoddart,et al.  Mesostructured multifunctional nanoparticles for imaging and drug delivery , 2009 .

[31]  Anjali Sharma,et al.  Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. , 2004, The Journal of antimicrobial chemotherapy.

[32]  Zongxi Li,et al.  Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. , 2010, Small.

[33]  K. Kisich,et al.  Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis. , 2007, International journal of pharmaceutics.

[34]  Monty Liong,et al.  Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. , 2008, ACS nano.

[35]  WHO global tuberculosis control report 2010. Summary. , 2010, Central European journal of public health.

[36]  Yaping Li,et al.  In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. , 2011, Small.

[37]  M. Garimoldi,et al.  Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease , 1972, Gut.

[38]  T. Bein,et al.  Bio-degradation study of colloidal mesoporous silica nanoparticles: Effect of surface functionalization with organo-silanes and poly(ethylene glycol) , 2010 .

[39]  D. Chiappetta,et al.  New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. , 2010, Advanced drug delivery reviews.

[40]  Zongxi Li,et al.  Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. , 2010, ACS nano.

[41]  L. Heifets,et al.  Nanoparticles as Antituberculosis Drugs Carriers: Effect on Activity Against Mycobacterium tuberculosis in Human Monocyte-Derived Macrophages , 2000 .

[42]  H. Swai,et al.  In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[43]  P. Devarajan,et al.  Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. , 2010, Journal of pharmaceutical sciences.

[44]  Saji George,et al.  Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs. , 2009, ACS nano.

[45]  K. Kisich,et al.  The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. , 2005, American journal of respiratory and critical care medicine.

[46]  J. Kaur,et al.  Inhalable microparticles containing large payload of anti-tuberculosis drugs. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[47]  Dong Chen,et al.  The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. , 2010, Biomaterials.

[48]  J. Feijen,et al.  The effect of phagocytosis of poly(L-lactic acid) fragments on cellular morphology and viability. , 1993, Journal of biomedical materials research.

[49]  Juan L. Vivero-Escoto,et al.  Mesoporous silica nanoparticles for intracellular controlled drug delivery. , 2010, Small.

[50]  H. Swai,et al.  In vivo uptake and acute immune response to orally administered chitosan and PEG coated PLGA nanoparticles. , 2010, Toxicology and applied pharmacology.